GlaxoSmithKline Steers Away from 'White Pills in Western Markets'
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Andrew Witty underlines the company's continued diversification into vaccines, consumer health and emerging markets
You may also be interested in...
GSK/Dr. Reddy’s Form Deal To Co-Promote Branded Generics In Emerging Markets
Strategic alliance expands GSK’s reach in emerging markets, just after deal in May with South African generics drug maker Aspen.
GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
Emerging markets present great opportunities, tempered by volatility, vastly different local environments, and ever-changing regulations.
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.